Oncology

Non-small cell lung cancer
#European Commission #Lung cancer #Oncology #Phase II trial #Pierre Fabre

EC approves new combination treatment for NSCLC

The European Commission (EC) has approved Braftovi (encorafenib) in combination with Mektovi (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation. The EC decision followw a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) issued on 25… Read More

#News #Regulatory

CAR-T therapy
#CAR-T #Cell therapy #China #Legend Biotech #Myeloma #Oncology

Legend Biotech secures China cilta-cel approval for multiple myeloma

Legend Biotech (a subsidiary of GenScript Biotech) has received approval from the China National Medical Products Administration (NMPA) for cell therapy product, ciltacabtagene autoleucel (cilta-cel). The treatment is approved for use in adults with relapsed or refractory multiple myeloma (MM) who have undergone at least three prior lines of therapy,… Read More

#News #Regulatory

Two scientists working in a research laboratory
#Cancer research #Cancer therapeutics #Funding #Innovate UK #Oncology

Cancer drug discovery projects receive £12 million

Twenty-three companies will benefit from a share of £12 ($15.8) million from the Innovate UK Cancer Therapeutics programme. The Cancer Therapeutics programme focuses on developing life-changing cancer treatments, including immunotherapies and vaccines. It also supports projects addressing unmet medical needs for treating childhood and young persons’ cancers. The investment from… Read More

#Business & Investment #Cancer Research #News

CAR-T cell therapy
#CAR-T #Cell and gene therapy #Cell therapy #Lymphoma #Oncology

The curative potential of CAR-T cell therapy

Dr Nicholas Siciliano, Co-Founder of Vittoria Biotherapeutics, shares insight on the VIPER-101 trial targeting T-cell lymphoma, the company’s aim to ensure progression free survival and opportunities in this sector.  MT: I understand that your lead programme is moving into the clinic, with POC human data expected in 2024. Can you… Read More

#Cancer Research #Exclusive Content

Urinary system
#Antibody drug conjugate (ADC) #Astellas Pharma #European Commission #Oncology #Urothelial carcinoma

EU okays new first-line treatment for advanced urothelial cancer

The European Commission has granted marketing authorisation for antibody-drug conjugate (ADC) Padcev (enfortumab vedotin) in combination with PD-1 inhibitor Keytruda (pembrolizumab) for urothelial cancer. It is approved for the first-line treatment of adult patients with unresectable or metastatic cancer, who are eligible for platinum-containing chemotherapy. The approval is based on… Read More

#News #Regulatory

Non-small cell lung cancer
#FDA #Johnson & Johnson #Lung cancer #Non-small cell lung cancer (NSCLC) #Oncology

FDA approves combination therapy for non-small lung cancer

The US Food and Drug Administration (FDA) has approved lazertinib (Lazcluze) in combination with amivantamab-vmjw (Rybrevant) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). It is approved in NSCLC with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations,… Read More

#News #Regulatory

#Funding #Investment #Oncology #Talus Biosciences #Transcriptomics

Talus raises $11.2M to target undruggable transcription factors

Talus Bioscience has raised $11.2 million in new venture funding from a Seed+ round. The funding round was led by Two Bear Capital, with participation from WRF Capital, NFX, YC Continuity Fund, Funders Club VC, and BoxOne Ventures. The money will be invested to advance Talus Bio’s therapeutic programmes, which… Read More

#Business & Investment #News

Monoclonal antibody
#AbbVie #European Commission #Follicular lymphoma #Genmab #Lymphoma #Oncology

Second lymphoma indication approval for Tepkinly in Europe

AbbVie and Genmab’s Tepkinly (epcoritamab) has been granted conditional marketing authorisation by the European Commission (EC) as a monotherapy for relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of prior therapy. The approval makes Tepkinly the first subcutaneous T-cell engaging bispecific antibody approved to treat both… Read More

#News #Regulatory

FDA headquarters
#Bispecific Antibodies #FDA #Oncology #Orphan drugs #Phanes Therapeutics

Neuroendocrine carcinoma drug granted orphan status

Phanes Therapeutics' PT217 has received orphan drug designation (ODD) for neuroendocrine carcinoma (NEC) from the US Food and Drug Administration (FDA). PT217 is a first-in-class bispecific antibody targeting delta-like ligand 3 (DLL3) and cluster of differentiation 47 (CD47) being developed for patients with NEC. NEC is known to be the… Read More

#Cancer Research #News #Regulatory

#Cancer drug targets #Cancer research #Cancer therapeutics #FDA #Oncology

New DDW Highlights podcast: 19 August 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. The chosen news highlights this week all feature advances in drug development in oncology… Read More

#News

#Cancer drug targets #Cancer research #Cancer therapeutics #FDA #Oncology

New DDW Highlights vodcast: 19 August 2024

Every week, DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates in the DDW Highlights podcast. It is now also available in a concise vodcast format.   The chosen news highlights this… Read More

#News

Tumour microenvironment
#CV6 Therapeutics #Oncology #Phase I trial #Solid tumours #University of Glasgow

Investigational therapy for advanced cancers enters trials

CV6 Therapeutics has initiated patient dosing in a Phase Ia clinical trial evaluating its investigational first-in-class, specific dUTPase inhibitor CV6-168 + infusional 5-fluorouracil (5-FU). The study will assess the safety, pharmacokinetic and pharmacodynamic profiles and anti-tumour activity for CV6-168 in the treatment of patients with advanced… Read More

#Cancer Research #News

#Cancer drug targets #Cancer research #Cancer therapeutics #FDA #Oncology

This week in drug discovery (12-16 August) 

News round-up for 12-16 August by DDW Senior Digital Content Editor Diana Spencer. The chosen news highlights this week all feature advances in drug development in oncology indications and reflect the breadth of therapeutic approaches to cancer treatment. The top stories: Genetic causes of… Read More

#News

T cell attacking cancer cell
#Cell therapy #Citius Pharmaceuticals #FDA #Lymphoma #Mergers and acquisitions #Oncology

Citius Oncology launches following FDA approval of Lymphir

The US Food and Drug Administration (FDA) has approved Lymphir (denileukin diftitox-cxdl) for the second-line treatment of r/r cutaneous T-cell lymphoma (CTCL), making it Citius Pharma’s first product approved in the US. Lymphir is a novel immunotherapy and the only CTCL therapy that targets the interleukin-2 (IL-2) receptor found on… Read More

#Business & Investment #News #Regulatory

Ovarian cancer cells
#Oncology #Panavance Therapeutics #PARP inhibitors #Preclinical development

New data support antitumour drug misetionamide in ovarian cancers

New published data have demonstrated positive monotherapy results for misetionamide as well as synergistic activity with PARP inhibitors (PARPis) and bevacizumab antineoplastic in ovarian cancer. Misetionamide is a tumour cell selective small molecule drug that is broadly active in multiple cancer models. Misetionamide’s inhibition… Read More

#Cancer Research #News

Gastric cancer
#Astellas Pharma #Gene mutation #MHRA #Monoclonal antibodies #Oncology

First claudin 18.2 biomarker targeted therapy licensed in Britain

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has licensed Astellas’ Vyloy (zolbetuximab), an anti-claudin 18.2 (CLDN18.2) monoclonal antibody. It is licensed in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric… Read More

#News #Regulatory